Tag: 6

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.

AKVA group ASA (“AKVA”) today hosts a Capital Markets Day where it introduces a revenue target of NOK 5 billion and an EBIT target of 9% for 2027 and outlines its ambitions for continued profitable growth to NOK 7 billion in 2030.

On 5 June 2025, the Annual General Meeting of Arco Vara AS adopted the decision to issue a targeted share offering to specific investors in order to increase the company’s share capital.
Arco Vara AS announces that the targeted share issue approved by the shareholders has been successfully completed as of 11 June 2025 – the management board has adopted a resolution to shorten the subscription period due to early subscription of issued shares. In accordance with the adopted decision of the general meeting:

5. juunil 2025 võttis Arco Vara ASi aktsionäride korraline üldkoosolek vastu otsuse viia läbi suunatud aktsiaemissioon kindlatele investoritele eesmärgiga suurendada ettevõtte aktsiakapitali.
Arco Vara AS teatab, et aktsionäride poolt heaks kiidetud suunatud aktsiaemissioon on edukalt lõpetatud 11. juunil 2025 – juhatus on võtnud vastu otsuse märkimisperioodi lühendamiseks seoses välja lastud aktsiate ennetähtaegse märkimisega. Vastavalt vastu võetud üldkoosoleku otsusele:

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax¹

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.